[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@LBR_ZA "$Roche and $SRPT two companies pushing science forward are being called criminals by clowns pretending to be journalists. Dont listen to the noise. Hold your shares. This is a one-of-a-kind treatment with billions behind it there will inevitably be a major outcome"
@LBR_ZA on X 2025-07-26 21:14:41 UTC XX followers, XXX engagements

"Even with Elevidys shipments paused $SRPT delivered solid Q2 2025 results: 🧬 $513M total revenue Elevidys (pre-pause): $282M PMO therapies: $231M Sarepta is not a one-drug company strong RNA revenue today and a promising siRNA pipeline for tomorrow"
@LBR_ZA on X 2025-07-22 11:26:34 UTC XX followers, XXX engagements

"@ilzizzo While panic and bad buzz hit $SRPT many forget the $850M cash siRNA pivot and shift to lower-risk future ARR. Perfect setup for sharks to buy cheap and ride the next wave. Most retail dont even know SRPTs real assets. Shame. 📉📈"
@LBR_ZA on X 2025-07-19 19:18:44 UTC XX followers, XXX engagements

"📉 $SRPT is trading at $XXXXX but XX% of shares are held by institutions (BlackRock Vanguard). 💥 Very low short interest (15%) = tiny float = massive short squeeze potential. 📆 Earnings on August X. If Roche and the FDA move forward the rebound could be explosive"
@LBR_ZA on X 2025-07-27 10:39:20 UTC XX followers, XXX engagements

"$SRPT will report Q2 earnings on August X. Theres a strong chance of a rebound if good news drops before then. Lets hope $Roche being involved helps accelerate resolution with the FDA"
@LBR_ZA on X 2025-07-27 10:28:12 UTC XX followers, XXX engagements